Safety and efficacy of DEB-TACE in combination with lenvatinib and camrelizumab for the treatment of unresectable hepatocellular carcinoma (uHCC): a two-centre retrospective study

Safety and efficacy of DEB-TACE in combination with lenvatinib and camrelizumab for the treatment of unresectable hepatocellular carcinoma (uHCC): a two-centre retrospective study

ObjectivesThe purpose of this study was to compare the safety and efficacy of drug-eluting bead (DEB) transarterial chemoembolization combined with lenvatinib and camrelizumab (DEB-TACE-Len-C) and DEB-TACE-Len for the treatment of unresectable hepatocellular carcinoma (uHCC).MethodsThis retrospectiv...

Full description

Bibliographic Details
Main Authors: Zhang Xuexian, Wang Ruidong, Ding Yuhan, Li Qingwei, Xiong Feng, Ren Hong, Zhang Jun, Li Wei
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-10-01
Series:Frontiers in Immunology
Subjects:
drug-eluting beads
transarterial chemoembolization
lenvatinib
camrelizumab
unresectable hepatocellular carcinoma
treatment
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1422784/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1422784/full

Similar Items